Dear Conference Participants and Colleagues,
On behalf of the Organizing Committee, I would like to welcome you to the "2018 Antibody Therapeutics Conference: Immuno-Oncology and Beyond" being held in National Biotechnology Research Park (Taipei, Taiwan) on Dec 4th, 2018. This is also the seventh Antibody Therapeutic Conference held in Taiwan.
The applications of antibody therapeutics remain a growing field today, especially in the treatment of cancers, immune-mediated diseases and infectious diseases, which all highlighting the critical pharmaceutical importance of antibody therapeutics. Particularly, immunotherapy including antibody-mediated tumor regression, checkpoint blockade, and adoptive cell therapy (ACT) acts as potential strategies to cure cancers.
This year the ATC conference focuses on understanding the immune checkpoints - beyond PD-1, tumor microenvironment, and cell therapy, in which the meeting is organized to highlight recent insights into the complex roles of immune components and pathways in controlling or alternatively promoting cancer and to showcase recent uses of checkpoint blocking strategies, modulation of tumor microenvironment, and adoptive cell therapeutics approaches, either as mono- or combinatorial therapies, that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients. Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to target or monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible in the past.
The mission of our Antibody Therapeutics Conference is to provide an international forum for the field of antibody discovery, antibody engineering, antibody therapeutics development and commercialization. We aim to provide opportunities for the attendants to have good connections and to assist the training and advancement of students, postdoctoral fellows and other new members in the field, in part through sponsorship of international scientific meetings.
Last but not least, we hope the meeting stimulated cross talks between senior experts and young Scientists Working on antibody therapeutics. This meeting not only provides a forum for sharing your insightful research but also a great opportunity to network with your fellow professionals.
We hope this meeting will contribute to the advancement of the field of the antibody therapeutics and you will find this meeting an informative, constructive and inspiring experience.
Lawrence Gan, Ph.D.
Director of Taiwan Antibody Association; President/CEO, Foresee Pharmaceuticals